Viral Protein Patents (Class 536/23.72)
-
Publication number: 20100034774Abstract: Adenovirus serotypes differ in their natural tropism. The adenovirus serotypes 2, 4, 5 and 7 all have a natural affiliation towards lung epithelia and other respiratory tissues. In contrast, serotypes 40 and 41 have a natural affiliation towards the gastrointestinal tract. The serotypes described differ in at least capsid proteins (penton-base, hexon), proteins responsible for cell binding (fiber protein), and proteins involved in adenovirus replication. This difference in tropism and capsid protein among serotypes has led to the many research efforts aimed at redirecting the adenovirus tropism by modification of the capsid proteins.Type: ApplicationFiled: July 23, 2009Publication date: February 11, 2010Applicant: Crucell Holland B.V.Inventors: Ronald Vogels, Angelique A.C. Lemckert, Menzo J.E. Havenga
-
Publication number: 20100034849Abstract: This invention relates to bicistronic flavivirus vectors, methods of using such vectors in the prevention and treatment of disease, and methods of making such vectors.Type: ApplicationFiled: January 31, 2008Publication date: February 11, 2010Applicant: Sanofi Pasteur Biologics Co.Inventors: Simon Delagrave, Nathan Brown, Harold Kleanthous, Farshad Guirakhoo, Alexander Rumyantsev
-
Publication number: 20100034852Abstract: The instant invention provides methods for determining, predicting and characterizing the genetic variability of viruses, in particular, influenza. Accordingly, the invention provides methods for identifying virulent pathogens, genetic mutations within pathogens that are relevant to animal health, and methods and compositions for prophylactic or therapeutic intervention against such pathogens.Type: ApplicationFiled: January 24, 2008Publication date: February 11, 2010Inventor: Henry L. Niman
-
Patent number: 7659103Abstract: The present invention provides a method for replicating efficiently an RNA containing fulllength HCV genomic sequence and a method for producing HCV virus particles containing fulllength HCV replicon RNA or fulllength HCV genomic RNA by using a cell culture system. Further, the present invention relates to a method for producing hepatitis C virus particles which comprises culturing a cell, into which a replicon RNA comprising a nucleotide sequence comprising a fulllength genomic RNA sequence of hepatitis C virus of the genotype 2a, at least one selectable marker gene and/or at least one reporter gene and at least one IRES sequence or the fulllength genomic RNA of hepatitis C virus of the genotype 2a is introduced, and generating virus particles in the culture medium. Still further the present invention relates also to a hepatitis C vaccine and an antibody against hepatitis C virus particles.Type: GrantFiled: February 21, 2005Date of Patent: February 9, 2010Assignees: Tokyo Metropolitan Organization For Medical Research, Toray Industries, Inc.Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto, Jun-ichi Tanabe, Saburo Sone
-
Publication number: 20100028375Abstract: An isolated protein comprising a VP1 amino acid sequence wherein one or more exposed loops within said VP1 has an insertion of an amino acid sequence from a virus protein other than VP1, and encoding nucleic acid, are provided. Typically, the virus protein other than VP1 is derived from an influenza virus and in particular, avian influenza virus. The isolated protein may have an insertion of amino acid sequence from a single protein or a plurality of proteins. Also provided are expression constructs, VLPs, pharmaceutical compositions, vaccines and methods of treatment that may be useful in the prophylactic and/or therapeutic treatment of any disease of viral origin, and in particular, influenza virus.Type: ApplicationFiled: October 4, 2007Publication date: February 4, 2010Applicant: The University of QueenslandInventors: Linda Hwee-Lin Lua, Anton Peter Jacob Middelberg
-
Publication number: 20100029751Abstract: The present invention provides a composition comprising (a) a parvovirus NS1 protein and (b) a parvovirus VP1 protein. Furthermore, the present invention provides DNA sequences encoding said proteins. The composition of the invention is useful for the preparation of a toxin for treating tumoral diseases.Type: ApplicationFiled: September 30, 2009Publication date: February 4, 2010Applicant: Deutsches Krebsforschungszentrum Stiftung des Offentlichen RechtsInventors: Laurent Daeffler, Jurg Nuesch, Jean Rommelaere
-
Publication number: 20100028377Abstract: The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant respiratory syncytial viral vectors and viruses are engineered to contain complete deletions of the M2-2, NS1, NS2, or SH viral accessory genes or various combinations thereof. In addition, the present invention relates to the attenuation of respiratory syncytial virus by mutagenisis of the M2-1 gene.Type: ApplicationFiled: May 4, 2009Publication date: February 4, 2010Applicant: MEDIMMUNE, LLCInventors: Hong Jin, Roderick Tang, Shengqiang Li, Martin Bryant, David Kirkwood Clarke, Peter Palese
-
Publication number: 20100029568Abstract: The invention provides compositions and methods for the treatment of HIV infection, inhibition against drug-resistant strains of HIV-1 and methods of enhancing the anti-HIV potency of peptide inhibitors against drug-resistant strains of HIV-1. In particular, oligomeric C-peptide inhibitors for inhibiting HIV entry into host cells are disclosed.Type: ApplicationFiled: March 12, 2008Publication date: February 4, 2010Applicant: THOMAS JEFFERSON UNIVERSITYInventors: Kristen Kahle, Suparna Paul, H. Kirby Steger, Michael J. Root
-
Patent number: 7655406Abstract: The invention concerns the use of cells capable of carrying out a process of prenylation of proteins coded by the hepatitis C virus (HCV) genome, such as prenylation of the NS5A protein, for replicating and, if required, the production of HCV or derivative viable mutants, in a suitable culture medium.Type: GrantFiled: October 2, 2007Date of Patent: February 2, 2010Assignee: Centre National de la Recherche ScientifiqueInventors: Czeslaw Wychowski, Gilles Duverlie, Jean Dubuisson, Andre Pillez
-
Publication number: 20100021484Abstract: The invention is directed to a poxvirus vaccine comprising a soluble truncated poxvirus envelope protein. The invention is also directed to a vaccine comprising a nucleic acid encoding such proteins. Also included is an antibody which specifically binds to the proteins and nucleic acid encoding the same, as well as methods of preventing and treating a poxvirus infection using the afore-mentioned vaccine, antibody, protein, and nucleic acid encoding them.Type: ApplicationFiled: June 23, 2009Publication date: January 28, 2010Inventors: Gary H. Cohen, Roselyn J. Eisenbert, John Charles Whitbeck, Lydia Aldaz-Carroll, Bernard Moss, Shlomo Lustig, Christiana Fogg
-
Patent number: 7652194Abstract: This invention describes a process for gene expression in plants utilizing translational vectors. Said translational vectors cause a gene of interest to be stably integrated into a transcriptionally active host genomic DNA such that the transcription of the gene of interest is controlled by a promoter of the host plant. Said translational vectors are preferably based on internal ribosome entry site (IRES) elements that are of plant origin.Type: GrantFiled: December 7, 2001Date of Patent: January 26, 2010Assignee: Icon Genetics GmbHInventors: Yuri Gleba, Victor Klimyuk, Gregor Benning, Serik Eliby
-
Publication number: 20100015687Abstract: The present invention is directed oncolytic Herpes simplex-1 viruses whose replication is controlled using a tetracycline operator/repressor system. The invention also includes DNA sequences used in making the viruses and methods in which these viruses are used in the treatment of cancer patients with solid tumors.Type: ApplicationFiled: September 2, 2009Publication date: January 21, 2010Applicant: The Brigham and Women's Hospital, Inc.Inventor: Feng Yao
-
Publication number: 20100008944Abstract: The invention generally provides therapeutic and prophylactic compositions that include a replication defective mutant HSV-2 virus having a mutation in a viral host shut-off protein, a herpes simplex virus having a mutation in a viral host shut-off protein and two additional mutations that render the virus replication defective, and related methods.Type: ApplicationFiled: July 26, 2006Publication date: January 14, 2010Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: David Knipe, Timothy Dudek
-
Publication number: 20100003273Abstract: The present invention encompasses isolated nucleic acids containing transcriptional units which encode a signal sequence of one flavivirus and an immunogenic flavivirus antigen of a second flavivirus. The invention further encompasses a nucleic acid and protein vaccine and the use of the vaccine to immunize a subject against flavivirus infection. The invention also provides antigens encoded by nucleic acids of the invention, antibodies elicited in response to the antigens and use of the antigens and/or antibodies in detecting flavivirus or diagnosing flavivirus infection.Type: ApplicationFiled: July 24, 2009Publication date: January 7, 2010Inventor: Gwong-Jen J. Chang
-
Publication number: 20100003281Abstract: The present invention relates to monoclonal antibody specifically binding to polypeptide(s) comprising the amino acid sequence as set forth in SEQ ID No.Type: ApplicationFiled: April 30, 2009Publication date: January 7, 2010Applicant: YANG SHENG TANG COMPANY LIMITEDInventors: Ningshao Xia, Jun Zhang, Ying Gu, Shaowei Li, Shengxiang Ge, Zhiqiang He
-
Publication number: 20090324623Abstract: The present invention discloses a two-component genome flavivirus and a method for propagating such virus. Since the genetic material of this flavivirus is distributed between two genomes, the flavivirus is deficient in replication, incapable of causing disease but capable of inducing an immune response. Nevertheless, the design of the replication deficient flavivirus discussed herein allows propagation of these flaviviruses at industrial level.Type: ApplicationFiled: May 7, 2008Publication date: December 31, 2009Inventors: Ilya V. Frolov, Alexandr V. Shustov
-
Publication number: 20090324553Abstract: The invention relates to chimeric polytropic viral envelope polypeptides and uses thereof, as well as to polynucleotides encoding said chimeric polypeptides and constructs comprising said polypeptides and/or polynucleotides. The invention also relates to chimeric retroviral envelope polypeptides, polynucleotides and vectors encoding said chimeric retroviral envelope polypeptides, virus particles and cells harbouring said chimeric envelope polypeptides. Said chimeric polypeptide comprise an envelope polypeptide, or fragment thereof, and a polypeptide sequence of a receptor binding region, ligand or polypeptide sequence of a ligand binding region, and optionally a linker sequence. The invention include methods of targeting receptors, methods of treatment and methods for delivery of agents using said chimeric retroviral envelope polypeptides. The invention is applicable for directed targeting and controlled fusion of virus particles with other cellular membranes.Type: ApplicationFiled: March 16, 2007Publication date: December 31, 2009Inventors: Finn Skou Pedersen, Shervin Bahrami, Mogens Ryttergaard Duch, Lars Ostergaard, Martin Tolstrup
-
Publication number: 20090325870Abstract: The present invention concerns the technical field of nucleic acids and expression-optimized nucleic acids. The present invention concerns especially nucleic acids comprising a mutated foamy viral envelope gene encoding a foamy viral envelope polypeptide, which comprises a leader peptide (LP), a surface unit (SU) and a transmembrane domain (TM). The present invention also relates to modified polypeptides encoded by these nucleic acids. Furthermore, the present invention regards a method for preparing pseudotyped vector particles as well as a method for treating a genetic disorder comprising administering a nucleic acid or a polypeptide encoded by that nucleic acid.Type: ApplicationFiled: June 27, 2008Publication date: December 31, 2009Applicant: VECTORIA FORSCHUNGSFOERDERUNGS VEREIN E.V., C/O INSTITUT FUR VIROLOGIE UND IMMUNBIOLOGIEInventors: Dirk Lindemann, Kristin Stirnnagel, Daniel Lueftenegger
-
Patent number: 7638120Abstract: The present invention related to methods and compositions comprising recombinant vectors comprising chimeric capsids and recombinant pseudotyped vectors with non-native capsid protein(s). The recombinant vectors of the invention confer an altered tropism that permits selective targeting of desired cells.Type: GrantFiled: May 1, 2003Date of Patent: December 29, 2009Assignee: Thomas Jefferson UniversityInventors: Yuhong Liu, Jia Luo, Matthew During
-
Publication number: 20090311280Abstract: Herpesvirus entry mediator (HVEM) is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and acts as a molecular switch that modulates T cell activation by propagating positive signals from the TNF related ligand, LIGHT (p30, TNFSF14), or inhibitory signals through the immunoglobulin superfamily member, B and T lymphocyte attenuator (BTLA). A novel binding site for BTLA is disclosed, located in cysteine-rich domain-1 of HVEM. BTLA binding site on HVEM overlaps with the binding site for the Herpes Simplex virus-1 envelope glycoprotein D (gD), but is distinct from where LIGHT binds, yet gD inhibits the binding of both ligands. A BTLA activating protein present in human cytomegalovirus is identified as UL144. UL144 binds BTLA, but not LIGHT, and inhibits T cell proliferation.Type: ApplicationFiled: December 9, 2005Publication date: December 17, 2009Applicant: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGYInventors: Timothy C. Cheung, Ian R. Humphreys, Karen G. Potter, Christopher A. Benedict, Carl F. Ware, Carl De Trez, Michael Croft, Mitchell Kronenberg
-
Publication number: 20090311287Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.Type: ApplicationFiled: August 30, 2007Publication date: December 17, 2009Applicant: Maxygen, Inc.Inventors: Doris Apt, Juha Punnonen, Alice M. Brinkman
-
Publication number: 20090305420Abstract: This invention relates to an SRSV detection kit comprising all antibodies against SRSV-related virus constituting peptides selected from the following peptide groups (a) to (k), respectively: (a) a peptide having an amino acid sequence represented by SEQ ID NO: 1, and the like, (b) a peptide having an amino acid sequence represented by SEQ ID NO: 2, and the like, (c) a peptide having an amino acid sequence represented by SEQ ID NO: 3, and the like, (d) a peptide having an amino acid sequence represented by SEQ ID NO: 4, and the like, (e) a peptide having an amino acid sequence represented by SEQ ID NO: 5, and the like, (f) a peptide having an amino acid sequence represented by SEQ ID NO: 6, and the like, (g) a peptide having an amino acid sequence represented by SEQ ID NO: 7, and the like, (h) a peptide having an amino acid sequence represented by SEQ ID NO: 8, and the like, (i) a peptide having an amino acid sequence represented by SEQ ID NO: 9, and the like, (j) a peptide having an amino acid sequence repreType: ApplicationFiled: July 7, 2009Publication date: December 10, 2009Applicants: JP AS REP BY DIR-GEN NATL INST OF INF DIS, DENKA SEIKEN CO., LTD.Inventors: Naokazu TAKEDA, Katsuro Natori, Tatsuo Miyamura, Kunio Kamata, Toshinori Sato, Seiya Sato
-
Publication number: 20090304745Abstract: Chimeric alphavirus particles and alphavirus replicon RNAs are provided including methods of making and using same. The alphavirus replicon RNAs comprise deletions in one or more nonstructural proteins. Methods of making, using, and therapeutic preparations containing the chimeric alphavirus particle are disclosed.Type: ApplicationFiled: August 10, 2009Publication date: December 10, 2009Inventors: John M. Polo, Silvia Perri, Kent Thudium, Zequn Tang
-
Publication number: 20090304683Abstract: The invention relates to the spike protein from the virus (SARS-CoV) that is etiologically linked to severe acute respiratory syndrome (SARS); polypeptides and peptide fragments of the spike protein; nucleic acid segments and constructs that encode the spike protein, polypeptides and peptide fragments of the spike protein, and coupled proteins that include the spike protein or a portion thereof; peptidomimetics; vaccines; methods for vaccination and treatment of severe acute respiratory syndrome; antibodies; aptamers; and kits containing immunological compositions, or antibodies (or aptamers) that bind to the spike protein.Type: ApplicationFiled: January 19, 2007Publication date: December 10, 2009Inventors: Dimiter S. Dimitrov, Xiaodong Xiao, Zhu Zhongyu
-
Publication number: 20090305344Abstract: Chimeric alphaviruses and alphavirus replicon particles are provided, including methods of making and using same. Specifically, alphavirus particles are provided having nucleic acid molecules derived from one or more alphaviruses and structural proteins (capsid and/or envelope) from at least two or more alphaviruses. Methods of making, using, and therapeutic preparations containing the chimeric alphavirus particle, are disclosed.Type: ApplicationFiled: February 17, 2009Publication date: December 10, 2009Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.Inventors: John M. POLO, Silvia PERRI, Kent THUDIUM
-
Patent number: 7626013Abstract: The inventors have isolated cloned cDNA encoding the RNA genome of Human Immunodeficiency Virus type 1 (HIV-1). Various clones are described, which encode different regions of the genome, including those regions encoding viral antigens or proteins. Hybridization results indicate the difference between the HIV-1 clones and those of HTLV-I and HTLV-II. The inventors have also produced a restriction map of the entire cloned genomic sequence in order to facilitate further subcloning and using the restriction fragments in other hybridization tests and in methods to express encoded sequences.Type: GrantFiled: June 6, 1995Date of Patent: December 1, 2009Assignees: Institut-Pasteur, Centre National de la Recherche ScientifiqueInventors: Marc Alizon, Francoise Barre Sinoussi, Pierre Sonigo, Pierre Tiollais, Jean-Claude Chermann, Luc Montagnier, Simon Wain-Hobson
-
Publication number: 20090291472Abstract: Codon-optimized nucleic acids encoding influenza polypeptides and uses of the nucleic acids and polypeptides for inducing immune responses are provided herein.Type: ApplicationFiled: July 27, 2009Publication date: November 26, 2009Inventors: Shan Lu, Shixia Wang
-
Patent number: 7622125Abstract: The present disclosure relates to vectors comprising polynucleotide sequences that encode HIV polypeptides. In particular, the disclosure relates polycistronic vector constructs comprising sequences that encode HIV polypeptides as a single polyprotein. Compositions comprising these vectors and sequences along with methods of using these vectors and sequences are also disclosed.Type: GrantFiled: May 5, 2005Date of Patent: November 24, 2009Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Jan zur Megede, Susan W. Barnett
-
Patent number: 7622300Abstract: Trans-lentiviral gene transfer vectors, vector systems, vector particles, and methods for transduction of primary nondividing cells using the same, are described. Further described are modifications to the gene transfer vectors that improve transduction efficiency and/or gene expression, e.g., by incorporating the cis-acting sequences, PPT-CTS and/or WPRE, and derivatives or analogs thereof.Type: GrantFiled: July 24, 2002Date of Patent: November 24, 2009Inventors: John C. Kappes, Xiaoyun Wu
-
Patent number: 7618642Abstract: The present invention relates to polynucleotides encoding immunogenic HIV type C polypeptides. Uses of the polynucleotides in applications including DNA immunization, generation of packaging cell lines, and production of HIV Type C proteins are also described.Type: GrantFiled: July 5, 2001Date of Patent: November 17, 2009Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Jan zur Megede, Susan Barnett, Ying Lian, Susan Engelbrecht, Estrelita Janse van Rensburg
-
Patent number: 7618802Abstract: The present invention provides a cDNA of a severe acute respiratory syndrome (SARS) coronavirus, recombinant SARS coronavirus vectors, and SARS coronavirus replicon particles. Also provided are methods of making the compositions of this invention and methods of using the compositions as immunogens and/or vaccines and/or to express heterologous nucleic acids.Type: GrantFiled: January 19, 2006Date of Patent: November 17, 2009Assignee: The University of North Carolina at Chapel HillInventors: Ralph S. Baric, Rhonda Roberts, Boyd Yount, Kristopher M. Curtis
-
Publication number: 20090281025Abstract: The present invention relates to novel therapies for cancer and, in particular, to therapies that are particularly suited to tumor cells resistant to other types of therapies, such as radiation therapy, chemotherapy, or a combinations thereof. The invention provides methods for identifying and implementing strategies to inhibit a transcription factor involved in promoting resistance and inhibition of apoptosis. The invention provides a compound that alters ATF2 activity, specifically amino-terminal fragments of ATF2 that retain the JNK binding domain. The invention provides methods for inhibiting tumor cell growth and for sensitizing tumor cells to apoptosis with such peptides.Type: ApplicationFiled: October 17, 2005Publication date: November 12, 2009Applicant: Mount Sinai School Of Medicine of New York UniversityInventors: Anindita Bhoumik, Ze'ev Ronai
-
Patent number: 7611837Abstract: Current methods for detecting influenza A subtype H5 virus, for example cell culture, haemagglutination-inhibition, fluorescent antibody and enzyme immunoassay, and reverse transcriptase polymerase chain reaction (RT-PCR) may have the disadvantages of low sensitivity and low specificity. Furthermore, such methods are relatively difficult to use, and may not be suitable for routine detection on a daily basis. The kit for detecting H5 virus of this invention may provide a user-friendly alternative that is relatively more sensitive and specific to H5 virus. The detection kit utilizes two specially designed primers A and B for the replication of H5 virus, and a specific capture probe for immobilizing the amplified viral RNA. An additional primer C is also designed for the detection of pathogenic H5 virus. The detection of H5 virus by the detection kit may be accomplished within one day if desired.Type: GrantFiled: September 27, 2001Date of Patent: November 3, 2009Assignee: Hai Kang Life Corporation Ltd.Inventors: Albert Cheung-Hoi Yu, Ka-Lun So, Lung-Sang Ko, Lok-Ting Lau
-
Patent number: 7611868Abstract: Recombinant adenoviruses comprising modified fiber proteins which expand the tropism of the adenovirus in comparison to wild-type virus are disclosed. The modified fiber proteins described herein contain a peptide ligand for a cell surface binding site other than CAR comprising a 14 amino acid core sequence containing both fixed and variable amino acid residues. The invention includes isolated nucleic acid molecules encoding the modified adenovirus fiber proteins disclosed, as well as recombinant vectors and host cells containing said nucleic acid molecules. Methods of identifying peptide ligands that bind to cell binding sites other than CAR are included comprising screening a phage-display library of peptide ligands expressed within an adenovirus fiber knob context on CAR-negative cells.Type: GrantFiled: May 10, 2004Date of Patent: November 3, 2009Assignee: Instituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.Inventors: Paolo Monaci, Laura Fontana
-
Publication number: 20090269365Abstract: The invention provides specific proteins encoded by the vaccinia genome that elicit an immune memory response and can be used for vaccines directed against variola (smallpox), monkeypox and other poxviruses. The invention provides antigens, polypeptides comprising antigens, polynucleotides encoding the polypeptides, vectors, and recombinant viruses containing the polynucleotides, antigen-presenting cells (APCs) presenting the polypeptides, immune cells directed against the epitopes, and pharmaceutical compositions. The invention additionally provides methods, including methods for preventing and treating infection, for killing infected cells, for inhibiting viral replication, for enhancing secretion of antiviral and/or immunomodulatory lymphokines, and for enhancing production of disease-specific antibody.Type: ApplicationFiled: April 20, 2006Publication date: October 29, 2009Applicant: UNIVERSITY OF WASHINGTONInventors: David M. Koelle, Lichen Jing
-
Publication number: 20090269367Abstract: The present invention provides methods of predicting increases in pathogenic virulence, morbidity, and/or mortality or expansion in pathogen populations within regions or into new regions by identifying cycles or ratios of increasing concentrations of a family of small peptides expressed in pathogens and provides compounds comprising the small peptides for treatment and prevention of pathogenic outbreaks.Type: ApplicationFiled: April 23, 2009Publication date: October 29, 2009Inventors: Samuel BOGOCH, Elenore S. BOGOCH, Samuel Winston BOGOCH, Anne Elenore BORSANYI
-
Publication number: 20090270488Abstract: Embodiments of the invention provide processes for the selection of HIV-1 subtype (clade) C isolates, selected HIV-1 subtype C isolates, their genes and modifications and derivatives thereof for use in prophylactic and therapeutic vaccines to produce proteins and polypeptides for the purpose of eliciting protection against HIV infection or disease. A process for the selection of HIV subtype isolates comprises the steps of isolating viruses from recently infected subjects; generating a consensus sequence for at least part of at least one HIV gene by identifying the most common codon or amino acid among the isolated viruses; and selecting the isolated virus or viruses with a high sequence identity to the consensus sequence. HIV-1 subtype C isolates, designated Du422, Du 151 and Du 179 (assigned Accession Numbers 01032114, 00072724 and 00072725, respectively, by the European Collection of Cell Cultures) are also provided.Type: ApplicationFiled: January 21, 2009Publication date: October 29, 2009Inventors: Robert Edward Johnston, Salim Abdol Karim, Lynn Morris, Ronald Swanstrom, Carolyn Williamson
-
Patent number: 7608699Abstract: The present invention provides novel peptides, nucleic acids, vectors, compounds, compositions and methods for regulating nuclear import. The present invention also relates to a lentiviral NLS, and methods of use thereof for inhibiting HIV pathogenesis and disease progression, and for gene delivery methods.Type: GrantFiled: December 29, 2004Date of Patent: October 27, 2009Assignee: Rockefeller UniversityInventors: Mark A. Muesing, Tshaka J. Cunningham
-
Patent number: 7608422Abstract: Nucleic acid constructs containing HIV-1 gag/pol and SIV gag or SIV env genes which have been mutated to remove or reduce inhibitory/instability sequences are disclosed. Viral particles and host cells containing these constructs and/or viral particles are also disclosed. The exemplified constructs and viral particles of the invention may be useful in gene therapy for numerous disorders, including HIV infection, or as a vaccine for HIV-1 immunotherapy and immunoprophylaxis.Type: GrantFiled: August 19, 2003Date of Patent: October 27, 2009Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventor: George N. Pavlakis
-
Publication number: 20090265816Abstract: The present invention relates to nucleic acid molecules found in the genome of the Citrus Leprosis Virus (CiLV), which is associated to Citrus Leprosis (CiL) disease. The cloned CiLV nucleic acid molecules can be used as probes or can be used to design oligonucleotide primers useful in assays, such as a polymerase chain reaction, for detecting the presence of CiLV in biological samples, particularly leaves, roots and other tissues or organs of plants, such as plants from the genera Citrus and Poncirus. The invention comprises introducing the mentioned nucleic acid molecules in cloning vectors and cloning the recombinant nucleic acid molecules in cells, such as prokaryotes (e.g., bacteria like E. coli), and eukaryotes (e.g., yeast, COS, CHO, and other cells). The cloned CiLV nucleic acid molecules are expressed in cells to provide immunogenic proteins which can be used to raise antibodies against the CiLV, which can then be used to detect the presence of the CiLV virus in biological samples.Type: ApplicationFiled: September 6, 2005Publication date: October 22, 2009Inventors: Renata Castiglioni Pascon, Ana Claudia Rasera Silva
-
Publication number: 20090265796Abstract: The invention provides an isolated and purified DNA molecule comprising at least one DNA segment, a biologically active subunit or variant thereof, of a circular intermediate of adeno-associated virus, which DNA segment confers increased episomal stability, persistence or abundance of the isolated DNA molecule in a host cell. The invention also provides a composition comprising at least two adeno-associated virus vectors.Type: ApplicationFiled: August 7, 2007Publication date: October 22, 2009Inventors: John F. Engelhardt, Dongsheng Duan
-
Publication number: 20090264356Abstract: Expression of the E4 orf 1 gene of Ad-36 alone has been discovered to be responsible for the increased insulin sensitivity observed in Ad-36 infected animals, including increased adipogenesis. Ad-36 E4 orf 1 protein can be used to increase insulin sensitivity and ameliorate diabetes. Additionally, drugs that mimic the action of Ad-36 E4 orf 1 protein could be found. Ad-36 E4 orf 1 could also be used to increase fat cells in lipodystrophy. We have also discovered that Ad-36 infection in human skeletal muscle cells increased differentiation and insulin independent glucose uptake. It is expected that infection with Ad-36 E4 orf 1 gene will also cause these effects.Type: ApplicationFiled: November 30, 2006Publication date: October 22, 2009Inventors: Nikhil V. Dhurandhar, Thomas C. Holland, Zhong Q. Wang
-
Publication number: 20090253184Abstract: Embodiments of the invention include E1 expressing cell lines that can be used in a variety of methods for production of an E1 defective adenovirus. In certain aspects a cell of the invention can be adapted to various culture conditions, e.g., suspension culture in serum free medium. In a further aspect, the cell lines allow isolation and subculture of E1-deleted recombinant adenoviruses in an environment free of replication competent adenovirus (RCA).Type: ApplicationFiled: January 23, 2009Publication date: October 8, 2009Applicant: Introgen Therapeutics, Inc.Inventors: Peter Clarke, Shuyuan Zhang, Hai Pham, Joe Senesac
-
Publication number: 20090252755Abstract: Embodiments described herein include nucleic acid sequences, which encode hepatitis C virus of strain HC-TN, genotype 1a, proteins and polypeptides and fragments thereof. Use of these compositions, and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV are also contemplated.Type: ApplicationFiled: April 2, 2008Publication date: October 8, 2009Inventors: Jens Bukh, Robert H. Purcell, Suzanne U. Emerson, Akito Sakai
-
Patent number: 7598071Abstract: The invention relates to infectious clones of parvovirus B19, methods of cloning infectious B19 clones, and methods of cloning viral genomes that have secondary DNA structures that are unstable in bacterial cells. A B19 infectious clone and methods of producing B19 infectious clones are useful for producing infectious virus. Infectious virus is useful for identifying and developing therapeutically effective compositions for treatment and/or prevention of human parvovirus B19 infections.Type: GrantFiled: July 9, 2004Date of Patent: October 6, 2009Assignees: The United States of America as represented by the Department of Health and Human Services, Institut National de Recherche ScientifiqueInventors: Kevin Brown, Ning Zhi, Peter Tijssen, Zoltan Zadori
-
Publication number: 20090246829Abstract: Isolated nucleic acid molecules comprising a gene segment from a rhesus rotavirus (RRV) or from one of three rhesus:human reassortant viruses are disclosed, including isolated nucleic acid molecules having a sequence selected from the group consisting of: SEQ ID NO: 1-14, inclusive, and isolated nucleic acid molecules encoding a protein having a sequence selected from the group consisting of SEQ ID NO: 15-28, inclusive, as well as variants of the isolated nucleic acid molecules.Type: ApplicationFiled: February 3, 2009Publication date: October 1, 2009Applicants: ServicesInventors: Deborah A. Buonagurio, Alice F. Georgiu, Robert A. Lerch, Bruce B. Mason, Shridhara C. Murthy, Ruth S. Rappaport, Mohinder S. Sidhu, Stephen A. Udem, Timothy J. Zamb
-
Publication number: 20090239933Abstract: The present invention relates to deoxyribozymes targeting and cleaving HCV RNA. More particularly, the present invention relates to deoxyribozymes and composition used for the inhibition of HCV replication and HCV-related diseases.Type: ApplicationFiled: August 1, 2006Publication date: September 24, 2009Inventors: Carolina Alfieri, Janie Trepanier, Jerome E. Tanner, Richard Momparler
-
Publication number: 20090239265Abstract: An isolated polynucleotides comprising a HBsAg-S coding sequence that is adapted to receive an insert coding sequence, within a part of the HBsAg-S coding sequence that encodes an exposed site within the external loop of HBsAgS, and still encode a HBsAg-S that is able to assemble into a VLP. Proteins encoded by the polynucleotides, recombinant VLP's and various uses thereof are also described.Type: ApplicationFiled: February 6, 2009Publication date: September 24, 2009Inventors: ERIC JAMES GOWANS, THOMAS BERNARD MACNAUGHTON, HANS JURGEN NETTER
-
Publication number: 20090232830Abstract: The present invention relates to modified HIV-1 envelope proteins which express epitopes that produce a broadly cross reactive neutralizing response, their methods of use and antibodies which bind to these epitopes.Type: ApplicationFiled: August 29, 2005Publication date: September 17, 2009Inventors: Gerald Quinnan, Fatim Cham, Guido Van De Groen
-
Publication number: 20090233868Abstract: Disclosed herein is a small 7 amino-acid peptide, corresponding to the C terminus of RRM2 of the human La protein that binds to the IRES element of hepatitis C virus RNA and its derivatives. This disclosure demonstrates that this 7-mer interacts with the HCV IRES element both in vitro and in vivo and can compete against cellular La protein in binding to the HCV RNA. It is also shown here that this 7-mer peptide is able to inhibit HCV-IRES mediated translation in vivo which, in turn, leads to decreased viral replication.Type: ApplicationFiled: September 24, 2008Publication date: September 17, 2009Inventors: Saumitra Das, Siddhartha Roy, Upasana Ray, Asit Kumar Manna, Tanmoy Mondal, Romi Gupta, Renuka Pudi, Sudhamani Sonny